Dasiglucagon
Also referenced as: Zegalogue
A stable glucagon analogue used to reverse severe hypoglycemia in diabetes.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Zegalogue is FDA-approved for severe hypoglycemia in people with diabetes aged 6 years and older.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A stable glucagon analogue used to reverse severe hypoglycemia in diabetes.
Zegalogue is FDA-approved for severe hypoglycemia in people with diabetes aged 6 years and older.
Effectiveness depends on available liver glycogen; it is not a treatment for the underlying cause of diabetes.
Why It's Being Studied
- Severe hypoglycemia
- Hepatic glucose release
Mechanism of Action
Glucagon-receptor activation prompts the liver to release glucose.
Glucagon-receptor activation prompts the liver to release glucose. Effectiveness depends on available liver glycogen; it is not a treatment for the underlying cause of diabetes.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Severe hypoglycemia
- Hepatic glucose release
- Subcutaneous approved medicine
Evidence Summary
Randomized induced-hypoglycemia studies demonstrated faster glucose recovery than placebo.
Higher tiers carry more weight. Filled tiers have evidence for Dasiglucagon; tap to read it.
- Randomized induced-hypoglycemia studies demonstrated faster glucose recovery than placebo.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Randomized induced-hypoglycemia studies demonstrated faster glucose recovery than placebo.
Reported Adverse Events in Research
- Nausea and vomiting are common; pheochromocytoma and insulinoma are contraindications.
Limitations of Current Evidence
- Effectiveness depends on available liver glycogen; it is not a treatment for the underlying cause of diabetes.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Dasiglucagon | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Dasiglucagon — prescribing label